When is the ideal timing for obtaining whole exome sequencing? Is the timing strategy tumor dependent?
What specific and actionable molecular derangements are identified by NGS to guide targeted therapy?
Are all NGS platforms created equally? How are they different?
How has the clinical trial landscape for precision oncology changed under the influence of NGS?
Why is whole genome sequencing with NGS uniquely applicable to patients with NSCLC?
Can you describe a specific patient example and tumor type where whole exome sequencing (WES) with NGS generated a safe and effective treatment option that would not have emerged empirically without NGS?
Based on the evidence available, how should we be integrating and incorporating ctDNA profiling — liquid biopsies — with tissue-based whole exome NGS, including longitudinal biopsies?
When evaluating the receptivity of a patient and tumor to immune checkpoint blockade, why are total mutational burden and genomic stability — chromosome deletions and additions — as important as expression of the IC receptor?
What do you see as the significance of the FDA approval of PD-1 inhibitors for all tumors with MSI? What other canonical driver mutations — BRAF, ALK, and others — of similar significance do you see coming down the road?
What is your detailed analysis of the results from ProfiLER Study evaluating NGS-based, whole exome molecular profiling in patients with advanced or refractory cancer?
A 42-year-old woman presented with a painful left thigh mass, a biopsy of which showed undifferentiated sarcoma. Neoadjuvant targeted therapy, radiotherapy and chemotherapy showed no response and metastases to lung. Lung nodule submitted ...
What is your current guidance about whether and/or how and when to integrate tests for circulating tumor DNA (ctDNA) into protocols for precision cancer medicine?